New Ultrasound Technique Offers Less Invasive Option for Prostate Cancer Treatment
For men diagnosed with localized prostate cancer, a new treatment option is now available, offering a potentially less burdensome alternative to traditional surgery or radiation. High-intensity focused ultrasound (HIFU) is now reimbursed by the French national health insurance system, providing a significant step forward in prostate cancer care. This innovative approach aims to minimize the often-debilitating urinary and sexual side effects associated with more aggressive treatments, while still effectively targeting the tumor. The availability of this treatment, beginning January 1, 2026, marks a shift towards more personalized and conservative cancer care strategies.
Prostate cancer remains a significant health concern globally. According to the American Cancer Society, it is estimated that in 2024, there will be 299,010 new cases of prostate cancer diagnosed in the United States. In France, approximately 60,000 men receive a prostate cancer diagnosis each year, with nearly one in six men being affected after the age of 60. It is the third leading cause of cancer-related deaths among men. The introduction of HIFU represents a significant advancement in the treatment landscape, offering a potentially curative option for localized cancers while preserving patients’ quality of life.
How Does HIFU Work?
HIFU utilizes high-intensity focused ultrasound waves to precisely target and destroy cancerous tissue within the prostate. Unlike traditional surgical methods, HIFU is a non-invasive procedure, requiring no incisions or radiation. The technology combines advanced imaging techniques with the precision of HIFU to deliver focused energy directly to the tumor, minimizing damage to surrounding healthy tissues. This targeted approach is particularly beneficial for men seeking to avoid the potential side effects associated with more radical treatments.
The Focal One system, developed by French medical device company EDAP TMS, is a key component of this innovative treatment. The system delivers ultrasound waves non-surgically and the treatment is personalized based on the individual patient’s prostate shape and tumor characteristics. The process involves focusing acoustic energy on the tumor, causing the tissue to heat up rapidly – reaching temperatures of up to 80°C – and ultimately leading to cell destruction. The formation and implosion of microscopic bubbles (cavitation) further contribute to the breakdown of cancerous cells.
Benefits and Efficacy of HIFU
Clinical studies have demonstrated the efficacy of HIFU in treating localized prostate cancer. A study conducted in 2024, following 10 years of research, confirmed the treatment’s carcinological effectiveness, showing results comparable to, and in some cases superior to, those achieved with surgery. Professor Pascal Rischmann, the principal investigator of the HIFI study, emphasized that the reimbursement of HIFU will provide patients with access to a less invasive and conservative treatment option. He also highlighted the advantages of HIFU, including its single-session nature, customizable treatment planning, and the ability to preserve options for future interventions.
One of the most significant benefits of HIFU is the reduction in side effects. Dr. Antoine Faix, president of the French Association of Urology (AFU), noted that the urinary and sexual consequences often feared by patients are significantly reduced with this treatment. This is a crucial consideration for men seeking to maintain their quality of life during and after cancer treatment. The ability to avoid more radical interventions also allows for a “therapeutic de-escalation,” offering a less aggressive approach for localized tumors.
What is Therapeutic De-escalation?
The term “therapeutic de-escalation” refers to the shift towards less intensive treatments when appropriate, particularly in cases where the risk of cancer progression is low. HIFU fits into this paradigm by offering a targeted and conservative option for men with localized prostate cancer, avoiding the potential complications associated with more extensive surgeries or radiation therapy. This approach aligns with a growing trend in oncology to personalize treatment plans based on individual patient characteristics and tumor biology.
The French Healthcare System and Innovation
The decision to reimburse HIFU treatment by the French national health insurance system demonstrates a commitment to embracing medical innovation and providing patients with access to cutting-edge therapies. The “forfait innovation” program, highlighted by the Haute Autorité de Santé (HAS), plays a crucial role in evaluating and integrating promising new technologies into the healthcare system. This program aims to accelerate the adoption of innovative treatments that offer significant benefits to patients. The HAS’s positive assessment of HIFU paved the way for its inclusion in the reimbursement scheme, making it accessible to a wider range of patients.
The French healthcare system’s proactive approach to innovation is particularly noteworthy in the context of cancer care. By supporting the development and implementation of new technologies like HIFU, France is positioning itself as a leader in providing high-quality, patient-centered cancer treatment. This commitment to innovation is essential for improving outcomes and enhancing the quality of life for individuals affected by this disease.
What to Expect During and After HIFU Treatment
The HIFU procedure is typically performed on an outpatient basis, meaning patients can return home the same day. During the procedure, the patient lies on their side while a specialized probe is inserted into the rectum. This probe delivers focused ultrasound waves to the prostate, targeting the cancerous tissue. The procedure is guided by real-time imaging, ensuring precise targeting and minimizing damage to surrounding structures.
Following the procedure, patients may experience some mild discomfort, such as urinary frequency or urgency. These symptoms are usually temporary and can be managed with medication. Most patients are able to resume their normal activities within a few days. Regular follow-up appointments are essential to monitor treatment response and ensure long-term effectiveness. The long-term outcomes of HIFU are still being studied, but initial results are promising, with many patients experiencing excellent cancer control and minimal side effects.
The availability of HIFU represents a significant advancement in the treatment of localized prostate cancer, offering men a less invasive and potentially more effective option. As research continues and more data become available, HIFU is likely to play an increasingly important role in the management of this common and often challenging disease.
Next Steps: Patients interested in learning more about HIFU treatment should consult with a qualified urologist to determine if it is an appropriate option for their individual case. Further information about prostate cancer and available treatment options can be found on the websites of leading cancer organizations, such as the American Cancer Society and the Prostate Cancer Foundation.
Worth a look